Poziotinib is an irreversible pan-HER inhibitor with IC50 values of 0.0032 µM, 0.0053 µM and 0.0235 µM for HER1, HER2 and HER4, respectively. Poziotinib inhibited phosphorylation of HER family and downstream signaling molecules, and induced apoptosis and G1 arrest. Moreover, poziotinib demonstrated potent antitumor activity in HER2 amplified gastric cancer cells, HER2-amplified breast cancer cells, and erlotinib-resistant NSCLC.

KEYWORDS: Poziotinib | supplier | HER inhibitor | HM781-36B | CAS [1092364-38-9] | CAS[1429757-68-5] | Non Selective (Phosphorylation Substrates) | EGFR | ErbB2-HER2 | ErbB4-HER4 | Inhibitor | Receptors | Gastric cancer | NSCLC | Breast cancer